{
    "id": 22736,
    "fullName": "AR L702H",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "AR L702H (also referred to as L701H) lies within the ligand binding region of the androgen receptor (UniProt.org). L702H results in broadening of the Ar ligand specificity in cell culture and is less responsive to androgen stimulation in the background of T878A (also referred to as T877A) (PMID: 20007693, PMID: 10569618).",
            "references": [
                {
                    "id": 5567,
                    "pubMedId": 10569618,
                    "title": "Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10569618"
                },
                {
                    "id": 3102,
                    "pubMedId": 20007693,
                    "title": "Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20007693"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 367,
        "geneSymbol": "AR",
        "terms": [
            "AR",
            "AIS",
            "AR8",
            "DHTR",
            "HUMARA",
            "HYSP1",
            "KD",
            "NR3C4",
            "SBMA",
            "SMAX1",
            "TFM"
        ]
    },
    "variant": "L702H",
    "createDate": "05/18/2016",
    "updateDate": "05/19/2016",
    "referenceTranscriptCoordinates": {
        "id": 146212,
        "transcript": "NM_000044",
        "gDna": "chrX:g.67711621T>A",
        "cDna": "c.2105T>A",
        "protein": "p.L702H",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16055,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, 27% (8/30) of patients with castration resistant prostate cancer demonstrated resistance to treatment with Xtandi (enzalutamide) and were found, via cell-free DNA testing, to have either an increased frequency of AR L702H from baseline or acquired AR L702H during treatment (PMID: 27148695).",
            "molecularProfile": {
                "id": 23387,
                "profileName": "AR L702H"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14168,
                    "pubMedId": 27148695,
                    "title": "Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27148695"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6940,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, prostate cancer patients harboring either AR amplification or AR T878A or AR L702H prior to Zytiga (abiraterone) treatment demonstrated they were less likely to experience a greater than or equal to 50% to 90% PSA decline and showed a worse overall survial (HR=7.33) and progression-free survival (HR=3.73) (PMID: 26537258).",
            "molecularProfile": {
                "id": 23387,
                "profileName": "AR L702H"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5973,
                    "pubMedId": 26537258,
                    "title": "Plasma AR and abiraterone-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26537258"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9510,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABBV-075 (Mivebresib) inhibited proliferation of prostate cancer cells with Ar L702H in multiple models (AACR 107th Annual Meeting; April 16-20, 2016, Abstract 4694).",
            "molecularProfile": {
                "id": 23387,
                "profileName": "AR L702H"
            },
            "therapy": {
                "id": 4028,
                "therapyName": "Mivebresib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7243,
                    "pubMedId": null,
                    "title": "ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/4694"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9701,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mivebresib (ABBV-075) inhibited ETS-family target gene expression and proliferation of an Xtandi (enzalutamide)-resistant prostate cancer cell line harboring AR T878A and AR L702H as well as an ETV1 fusion in culture (PMID: 27707886).",
            "molecularProfile": {
                "id": 26987,
                "profileName": "ETV1 fusion AR L702H AR T878A"
            },
            "therapy": {
                "id": 4028,
                "therapyName": "Mivebresib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7485,
                    "pubMedId": 27707886,
                    "title": "Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27707886"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23387,
            "profileName": "AR L702H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26987,
            "profileName": "ETV1 fusion AR L702H AR T878A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 146212,
            "transcript": "NM_000044",
            "gDna": "chrX:g.67711621T>A",
            "cDna": "c.2105T>A",
            "protein": "p.L702H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}